SCRIPT used in 70% of medical schools around the UK

13th October 2021

SCRIPT is now being used in 30 of the 43 medical schools in the UK to support undergraduate training in prescribing and therapeutics. Dr Sarah Pontefract, Programme Director for SCRIPT and Senior Lecturer in Clinical Pharmacy and Therapeutics at the University of Birmingham said: 

“Our aim has always been to standardise education and training in prescribing and therapeutics to improve medicines safety. The increased uptake of SCRIPT in undergraduate medical schools is an important step in ensuring that the future prescribing workforce have the knowledge and skills to optimise treatment for patients, which includes reducing over-prescribing.”

For more information, visit: https://www.birmingham.ac.uk/university/colleges/mds/news/2021/09/script-elearning-programme.aspx

More News

SCRIPT eLearning Shortlisted for Prestigious HSJ Patient Safety Award

SCRIPT eLearning is delighted to announce that it has been shortlisted in the ‘Patient Safety Education and Training’ category of the HSJ Patient Safety Awards 2026, recognising its ongoing contribution to improving safety in prescribing and medicines management. The...

Birmingham Education for Health Professional Conference 2026

The SCRIPT team was delighted to present a poster at the Birmingham Education for Health Professional Conference 2026, led by our Research Associate Divya Singh. The poster, titled "eLearning in Multidisciplinary Prescribing Education: A Longitudinal Evaluation...

New Modules Under Development

We are committed to developing and adding new modules to ensure the SCRIPT programme continues to reflect current clinical practice and meets our learners’ changing needs. We have several modules at various stages of development, including Drugs of Addiction and...

Updated module – Diabetes: Antihyperglycaemic Medicines

NICE has recently updated its guidance on ‘Type 2 diabetes in adults: management’. In a change to national guidance modified‑release metformin alongside an SGLT2 inhibitor is now recommended as first‑line treatment for adults with type 2 diabetes mellitus....